RadNet Completes Acquisition of iCAD, Enhancing AI-Powered Breast Cancer Detection Capabilities

RadNet has completed the acquisition of iCAD, a global leader in AI-powered breast health solutions. The integration of iCAD's capabilities into DeepHealth, RadNet's digital health segment, positions DeepHealth to address clinical and operational challenges in screening and diagnosis by harnessing AI and imaging. The acquisition expands RadNet's market access to over 10 million mammograms annually and aims to accelerate AI adoption and screening compliance worldwide.

RadNet, Inc. (NASDAQ: RDNT), a leading national provider of diagnostic imaging services and digital health solutions, has completed the acquisition of iCAD, Inc. (NASDAQ: ICAD), a global leader in AI-powered breast health solutions. The acquisition, facilitated through RadNet's wholly-owned subsidiary DeepHealth, integrates iCAD's extensive AI portfolio into DeepHealth's screening solutions, enhancing RadNet's capabilities in breast cancer detection and management.

iCAD's technology, deployed in over 50 countries and more than 1,500 healthcare provider locations, includes solutions for breast cancer detection, risk evaluation, breast density assessment, and arterial calcification analysis. The acquisition aims to expand RadNet's global reach to over 10 million mammograms annually, significantly increasing market penetration and accelerating AI adoption in breast cancer screening.

The combined entity will integrate iCAD's AI portfolio with DeepHealth's existing solutions, creating a comprehensive suite of AI tools that could improve cancer detection rates and workflow efficiency. The acquisition addresses critical challenges in breast cancer screening, including early detection accuracy, large-scale program management, and extending advanced diagnostic capabilities to underserved communities.

RadNet's acquisition of iCAD strengthens its Digital Health segment's competitive position and creates new revenue opportunities through an expanded global customer base. The deal aligns with the broader healthcare industry trend toward AI-augmented clinical decision support systems that can address radiologist shortages while maintaining or improving diagnostic accuracy.

The acquisition is expected to have a significant impact on RadNet's business and future financial and operating results. The company anticipates that the integration of iCAD's capabilities will enhance DeepHealth's mission to address clinical and operational challenges in screening and diagnosis by harnessing the power of AI and imaging.

References:

[1] https://www.stocktitan.net/news/RDNT/rad-net-s-wholly-owned-subsidiary-deep-health-completes-acquisition-6yi1ntf43sus.html